Policy

FDA approves quicker reviews for new medications

Published in Medical Letter on the CDC and FDA, April 14th, 2002

The U.S. Food and Drug Administration (FDA) has reached an agreement with the drug companies it regulates to speed the review of new medications, in return for tens of millions of dollars in new industry fees.

The industry has long funded a significant portion of the FDA's drug review work. But for the first time, this agreement would allow some of that money to go to improved safety monitoring of new drugs - allowing the FDA to eventually double its number of staffers who oversee the risks of newly sold therapies.

Health and Human Services Secretary Tommy Thompson called that part of the deal essential to protecting public health.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2002-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry